음성 바이오마커 시장 보고서 : 동향, 예측 및 경쟁 분석(-2035년)

Vocal Biomarker Market

The future of the global vocal biomarker market looks promising with opportunities in the hospital and clinic markets. The global vocal biomarker market is expected to reach an estimated $9.6 billion by 2035 from $3.1 billion in 2027 with a CAGR of 12.5% from 2027 to 2035. The major drivers for this market are the increasing prevalence of voice disorders, the growing adoption of ai technologies, and the rising demand for remote diagnostics.

• Lucintel forecasts that, within the type category, frequency is expected to witness the highest growth over the forecast period due to rising demand for frequency-based solutions in sophisticated electronic systems.
• Within the application category, hospital is expected to witness higher growth over the forecast period due to developing hospital infrastructure. New advanced medical equipment is being used.
• In terms of regions, APAC is expected to witness the highest growth over the forecast period due to growing healthcare infrastructure and greater medical technologies investment within economies.

Emerging Trends in Vocal Biomarker Market

Between 2025 and 2027, the vocal biomarker market will shift from proof of concept to clinical decision support. Speech-based data will flow into remote monitoring, behavioral health, neurology, and wellness workflows. Lucintel sees this market shift toward validated, reimbursable AI, rather than novelty demonstrations.

• Clinical Validation: Voice-based screening reached 80% sensitivity for detecting depression in one study reported by researchers in March 2025. Vendors are progressing toward prospective studies and clinically important outcomes. This will drive purchasing decisions because hospitals will need technology that shows consistent outcomes for accent detection, different devices, and varied clinical settings.
• Multimodal AI: Leading AI technologies were combining speech and acoustic signals with metadata and transcriptions by patient by June 2025. Healthcare technologies that integrate voice data and signals are able to identify early stages of Parkinson's and other respiratory illnesses. Multimodal systems will improve triage, while increasing explainability.
• Privacy Preserving Analytics: The focus of AI companies within healthcare in 2025 was placed on a shift to on-device processing and limited transfer of data to alleviate the risk of data breaches. This approach facilitates compliance and will continue to inform technology procurement through 2030.
• Remote Monitoring: In January 2026, digital health technologies incorporated voice assessments into smartphone check-ins, thereby enabling measurement of health indicators outside of the hospital. Frequent measurement will drive adoption of voice-based technologies for the monitoring of chronic health conditions and will provide recurrent software revenue to technology developers.
• Reimbursement and Workflow Integration: In 2025, vocal biomarker technologies were integrated into workflows along with other telehealth and EHR technologies. Integration of vocal biomarker technologies along clinician dashboards that support billable care pathways will ensure a shift from pilot to enterprise contracts.

In the next three to five years, payors will consider clinical evidence and workflow more than organizational novelty in adoption decisions. Potential buyers will be more interested in technologies that reduce assessment time or systems that expand the capacity of specialists. Vendors in this space with larger speech datasets, more transparent validation efforts, and reimbursement models will get a greater share of the market with room for growth. Wellness technologies that make unsupported claims will face more scrutiny from both buyers and government agencies.

Recent Developments in the Vocal Biomarker Market

The vocal biomarker market is moving toward reimbursable clinical use cases and workflows. During 2025-2027, with more speech AI companies gaining partnerships with hospitals and expanding their coverage for diseases, and with more companies focusing on fulfilling regulatory requirements, we anticipate market activity to increase. Lucintel's perspective aligns with market shifts; validated outcomes and privacy controls, in addition to the ability to integrate with other systems, are now priorities for healthcare organizations.

• Hospital Partnerships: One of the major health systems in the US started a large trial in March 2025 to assess respiratory and neurological screening using voice technology to recruit 2,000 participants. These contracts provide real-world data, clinical validation, and purchasing access for the vendors over the next 3 to 5 years.
• Regulatory Validation: In January 2025, the FDA released their AI/NLS Policy Framework. There are now more defined parameters within the four evidence areas. This is expected to shift focus for companies from wellness to validated outcomes for their products.
• Platform Integration: With the release of Dragon Copilot in March 2025, Microsoft has brought together their existing speech technology for clinical documentation along with other ambient AI technologies. This has set a new standard for workflow integration and analysis within healthcare software.
• Privacy-preserving Deployment: In February 2025, the EU began implementation of the first obligations of the AI Act. These will impact high risk systems. This will set the standard for whether vocal biomarker technologies will be allowed in hospitals and other public sector procurement in the EU.
• Disease Expansion: In April 2025, some teams reported using multiple condition screening models with over 10,000 voice recordings. More extensive and diverse data should improve performance beyond single-disease models and aid the expansion of subscription services in primary care, remote monitoring, and drug trials.

The first companies to sell voice-activated diagnostic tools for use in clinical practice will likely not be those that have the largest voice datasets. Rather, they will be the first to get their tools to convert voice signals into clinically accepted diagnostic decisions. For 2025 to 2027, partnership-led validations, regulated pathways under the Digital Health Software, and privacy-safe deployments should inform purchasing decisions. The market will remain fragmented; however, hospital contracts and repeated reimbursement cases will make switching more expensive across care delivery systems.

Strategic Growth Opportunities in the Vocal Biomarker Market

Between 2024 and 2026, the vocal biomarker market transforms from research pilots to paid clinical and enterprise deployments. Improved Generative AI is being used to process and interpret speech. There is increased demand for low-cost monitoring created by aging populations and the growth of remote care. Commercial opportunities for vocal biomarkers are stronger when validated voice signals can fill existing workflows and be justified by reimbursement models.

• Remote Respiratory Monitoring: Voice-based technology can collect cough, breathing, and vocal signals without the need for additional hardware. A study published in February 2025 analyzed 1,000 speech recordings to identify respiratory symptoms. In the next three to five years, remote vocal biomarker technology will be used in virtual wards and other remote care services to lower monitoring costs while improving timeliness of response to the care recipient.
• Neurological Disease Assessment: The long span of the disease process for some disorders, such as Parkinson's or Alzheimer's, lends itself to the collection of longitudinal speech-based data. An April 2025 clinical dataset containing 5,000 vocal samples for Parkinson's was a first of its kind. It is expected that clinical demand will be high when key professionals can get reliability, validity, and evidence to support assessment and evaluation of clinical and research programs.
• Behavioral-health Screening: Assessment of depressive symptoms and anxiety via vocal features can be done within the context of a telehealth assessment, for example. A June 2025 study demonstrated 82% sensitivity for detection of depressive symptoms. Health systems will invest in decision-support tools that shorten assessments within the boundaries of clinician judgment.
• Enterprise Wellness Analytics: Voice signals, with appropriate controls for privacy and consent, can be used in contact centers and occupational health to identify employee stress and fatigue. In September 2025, a single employer pilot was carried out for 2,400 employees. This segment will expand as employers foster a culture of employee wellness in relation to absenteeism, retention, and service quality.
• Integrated and Privacy-Driven Systems: For regional languages and on-device processing to protect data, localized languages can reach beyond English-speaking countries. In March 2026, a public benchmark included models for 12 languages. In the next three to five years, local validation and data sovereignty rules, along with flexible APIs, will differentiate the scalable speech analytics providers from the rest.

The winners in the commercial market will integrate clinical evidence along with the use of iterative and sustainable software that enables recurring revenue based on a transparent consent model. Customers will be hesitant to believe claims of the most accurate systems unless they are externally validated. The most successful companies will offer focal outcomes for workflows and maintain large datasets, as well as secure payments for services or budgets. Partnerships with hospitals, insurance companies, and technology companies will improve the pace of adoption, but the privacy regulations will ensure careful purchasing.

Vocal Biomarker Market Drivers and Challenges

Changes in technology, economics, and regulations are affecting the vocal biomarker market. There is increasing market demand for voice-based health information due to the interest in remote health care, the use of AI and other tools in preventive and individualized medicine, etc. Concerns such as data privacy, no clinical validation, uncertainty regarding reimbursement, and inequities in digital access are barriers to market growth. Lucintel states that the first movers in the market will have an advantage while others may struggle. Lucintel implies that market success will depend on balancing the strengths of the healthcare system such as evidence, innovation, affordability, and responsible governance.

Driving forces for the vocal biomarker market include:

• Customer Demand: Growing customer demand for easy-to-use, noninvasive, and remote health data is creating interest in voice as a new clinical data source. In 2025, the World Health Organization continued to report that noncommunicable diseases accounted for approximately 74% of global deaths, thereby creating demand for scalable screening tools. Over the next three to five years, aging and chronic disease populations, coupled with enhanced virtual visits, will also drive demand for technologies that assess risk and prevent frequent clinic visits.
• AI Innovations: AI innovations will play a key role in advancing vocal biomarkers. Neurologic, cardiovascular, respiratory, and mental health conditions may be identified by vocal biomarkers. In particular, multimodal AI systems will play a critical role. The processing of speech, AI innovations, new regulations, and tools will create a more open development system for high-risk AI innovations. Over the next three to five years, innovations will provide new vocal biomarker tools that can be used on existing platforms and systems.
• Regulatory Support and Clinical Advances: Increased attention to digital health by regulators is driving the desire to seek clinical validation and adopt measurable benchmarks together with safer deployment. In August 2025, more detailed requirements of the European Union Artificial Intelligence Act applicable to high-risk AI systems, will better define the documentation and oversight required. In the next 3 to 5 years the combination of more consistent regulations and higher evidentiary standards should allow hospitals to partner with developers of commercial digital health products that deliver clinically meaningful services and separate those that do not.
• Preventive and Personalized Healthcare: Healthcare is shifting from a model of episodic care to a model of early detection and continuous care interventions that are personalized. Some vocal biomarkers have the capability of longitudinally monitoring health status and may be useful in developing individualized care plans. In January 2025, the Centers for Disease Control and Prevention continued to estimate that six in ten United States adults have at least one chronic disease, and there is a strong need for improved healthcare monitoring. In the next 3 to 5 years, voice technologies will increasingly be adopted within the framework of preventive health care as they complement standard healthcare examinations and laboratory tests.
• Manufacturing and Cost Efficiency: Software-based vocal biomarker products can operate using existing smartphones, microphones, and cloud technologies, and consequently do not require specific hardware. As of March 2025, smartphone connections numbered in the billions globally, showing the vast base available for voice applications on mobile devices. In the next three to five years, creation and deployment of vocal biomarker technologies in the cloud, along with reusable AI models and automation of data processing, should substantially decrease cost of development and upkeep, thus allowing smaller companies and under developed regions to utilize these technologies as long as the requisite cyberspace and security infrastructure is available and maintained.

This Market has the following challenges:

• Clinical Validation: Vocal Biomarker applications currently require large, diverse studies to demonstrate the biomarker's reliability across accents, languages, age groups, devices, and stages of the disease. As of April 2025, standards for clinical research continued to focus on the enrollment of diverse populations and the publication of research that provides evidence for the artificial intelligence health care tools. In the next three to five years, insufficient validation will most likely delay regulatory approval, slowdown physician use of vocal biomarkers, and prohibit reimbursement, and unwarranted diagnoses or missed diagnoses would erode public trust. Developers will need to undertake standardized testing in this new field and publish evidence of the impact of vocal biomarker technology on the clinical outcomes of patients as opposed to simply correlating vocal biomarkers to disease states.
• Privacy and Data Security: Voice recordings capture identity and emotion, health information, and context, which may not remain private. In January 2025, the General Data Protection Regulation continued placing burdens on the processing of personal data in the EU, and additionally addressed consent, security, and user control. The next 3 to 5 years may see breaches, unclear or poorly managed consent, or the use of data for a purpose unrelated to the original, slow adoption and increase cost of compliance. To maintain patient trust and compliance with the law, vendors must offer data encryption, minimize data, local processing where possible, explainable consent, and strong data governance.
• Reimbursement and Interoperability: Paying for vocal biomarkers may also be a disincentive to both hospitals and payers. Calculation of economic value may also be a barrier, as are gaps in electronic health records integration. In October 2025, healthcare organizations continued the balancing act of cost containment and growth of digital services. The next few years will likely see sluggish market growth due to fractured systems, uncertain reimbursement, and workflow disruption. Vendors can overcome the challenges of market growth by showing a positive impact on outcomes with lower hospital stays or greater productivity in clinician workflow, while utilizing established standards for interoperability and integrating tools seamlessly within digitization.

The market for vocal biomarkers has growth potential with user demand and the development of cost-effective software. Market growth can be challenged by the lack of clinical evidence and data validation, privacy concerns, and lack of reimbursement. Compelling evidence, data protection, and affordable solutions could allow a company to dominate the market for the next five years. Even more important will be systems and solutions that are easily integrated into healthcare systems and used across a range of settings and in varied populations.

List of Vocal Biomarker Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies vocal biomarker market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the vocal biomarker market companies profiled in this report include-

• Beyond Verbal Communication
• Sonde Health
• IBM
• Cogito

Vocal Biomarker Market by Segment

The study includes a forecast for the global vocal biomarker market by type, application, and region.

Vocal Biomarker Market by Type [Value ($B) from 2019 to 2035]:

• Frequency
• Amplitude
• Error Rate
• Phonation Time
• Pitch
• Others

Vocal Biomarker Market by Application [Value ($B) from 2019 to 2035]:

• Hospitals
• Clinics
• Others

Vocal Biomarker Market by Region [Value ($B) from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Vocal Biomarker Market

The vocal biomarker market is switching from research to regulated, embedded healthcare. Between 2025 and 2027, the market will mature with AI governance and clinically validated partnerships with medical device companies. Lucintel reports that, from 2025 until 2027, vendors will design vocal biomarkers along the lines of evidence, interoperability and compliance with privacy.

• United States: Regulatory validation and healthcare partnerships continue to be most important. In January 2025, the FDA released draft guidance concerning the lifecycle management of AI-enabled devices, including voice-based diagnostic devices. These companies will continue to develop voice-based screening devices. Sonde Health and Canary Speech are examples. The FDA draft proposes better defining the evidence and lowering the uncertainty for hospital integrations, as well as device integrations.
• China: Healthcare digitization supported by the state is advancing voice-AI. The 2025 Government Work Report targeted more than 10 million intelligent computing units. While major tech companies built medical AI and speech technologies, public investment will provide the computing to train vocal biomarkers for hospital and consumer health services.
• Germany: European compliance requirements are the most significant, commercial considerations. In February 2025, the first major components of the EU AI Act came into force, along with the prohibited practices and requirements for AI-literacy. German firms such as adhering continue their work in emotion and health-related voice analytics. Compliance will decide if vocal biomarker research will be able to migrate to certified clinical use.
• India: With the help of public institutions, digital health infrastructure in India has created systems for voice-enabled health screening. In March 2025, the Union government reported 76 crore Ayushman Bharat Digital Health Accounts and continued to invest in both health records and telemedicine. This digital infrastructure provides a foundation to implement vocal biomarkers, especially in rural areas in India that have high population densities and are multilingual.
• Japan: The Japanese government promotes the adoption of safe and responsible medical AI and complementary technologies such as robotic and remote assisted care. The AI Promotion Act of Japan was passed in May 2025. Domestic companies in the fields of electronic devices and health care are now evaluating voice control systems and monitoring applications since user interfaces will be regulated in the future. These provisions and an aging population will facilitate the introduction of vocal biomarker technologies into the domains of home and health care in Japan.

Features of the Global Vocal Biomarker Market

• Market Size Estimates: vocal biomarker market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
• Segmentation Analysis: vocal biomarker market size by type, application, and region in terms of value ($B).
• Regional Analysis: vocal biomarker market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the vocal biomarker market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the vocal biomarker market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the vocal biomarker market by type (frequency, amplitude, error rate, phonation time, pitch, and others), application (hospitals, clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 6 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Vocal Biomarker Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 Frequency: Trends and Forecast (2019-2035)
• 4.4 Amplitude: Trends and Forecast (2019-2035)
• 4.5 Error Rate: Trends and Forecast (2019-2035)
• 4.6 Phonation Time: Trends and Forecast (2019-2035)
• 4.7 Pitch: Trends and Forecast (2019-2035)
• 4.8 Others: Trends and Forecast (2019-2035)

5. Global Vocal Biomarker Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Hospitals: Trends and Forecast (2019-2035)
• 5.4 Clinics: Trends and Forecast (2019-2035)
• 5.5 Others: Trends and Forecast (2019-2035)

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Vocal Biomarker Market by Region

7. North American Vocal Biomarker Market

• 7.1 Overview
• 7.2 North American Vocal Biomarker Market by Type
• 7.3 North American Vocal Biomarker Market by Application
• 7.4 United States Vocal Biomarker Market
• 7.5 Mexican Vocal Biomarker Market
• 7.6 Canadian Vocal Biomarker Market

8. European Vocal Biomarker Market

• 8.1 Overview
• 8.2 European Vocal Biomarker Market by Type
• 8.3 European Vocal Biomarker Market by Application
• 8.4 German Vocal Biomarker Market
• 8.5 French Vocal Biomarker Market
• 8.6 Spanish Vocal Biomarker Market
• 8.7 Italian Vocal Biomarker Market
• 8.8 United Kingdom Vocal Biomarker Market

9. APAC Vocal Biomarker Market

• 9.1 Overview
• 9.2 APAC Vocal Biomarker Market by Type
• 9.3 APAC Vocal Biomarker Market by Application
• 9.4 Japanese Vocal Biomarker Market
• 9.5 Indian Vocal Biomarker Market
• 9.6 Chinese Vocal Biomarker Market
• 9.7 South Korean Vocal Biomarker Market
• 9.8 Indonesian Vocal Biomarker Market

10. ROW Vocal Biomarker Market

• 10.1 Overview
• 10.2 ROW Vocal Biomarker Market by Type
• 10.3 ROW Vocal Biomarker Market by Application
• 10.4 Middle Eastern Vocal Biomarker Market
• 10.5 South American Vocal Biomarker Market
• 10.6 African Vocal Biomarker Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunities by Type
  • 12.2.2 Growth Opportunities by Application
• 12.3 Emerging Trends in the Global Vocal Biomarker Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis
• 13.2 Beyond Verbal Communication
  • Company Overview
  • Vocal Biomarker Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Sonde Health
  • Company Overview
  • Vocal Biomarker Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 IBM
  • Company Overview
  • Vocal Biomarker Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Cogito
  • Company Overview
  • Vocal Biomarker Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us